patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus placebo - for COVID-19 mild to moderate
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.62 [0.43, 0.90]< 1 0% 2 studies (2/-) 99.4 % some concern not evaluable moderate crucial - deaths 0.60 [0.46, 0.80]< 1 0% 6 studies (6/-) 100.0 % some concern not evaluable moderate crucial - deaths (time to event analysis only) 0.70 [0.40, 1.21]< 1 0% 1 study (1/-) 89.9 % NA not evaluable crucial - clinical deterioration 0.40 [0.29, 0.55]< 1 13% 2 studies (2/-) 100.0 % low not evaluable high important - clinical improvement 1.39 [0.76, 2.54]> 1 0% 1 study (1/-) 85.8 % NA not evaluable important - clinical improvement (7-day) 0.90 [0.77, 1.06]> 1 0% 1 study (1/-) 9.7 % NA not evaluable important - clinical improvement (time to event analysis only) 1.40 [0.91, 2.15]> 1 0% 1 study (1/-) 93.8 % NA not evaluable important - death or ventilation 0.65 [0.50, 0.86]< 1 0% 2 studies (2/-) 99.9 % some concern not evaluable moderate important - hospital discharge 1.38 [1.04, 1.84]> 1 0% 2 studies (2/-) 98.7 % some concern not evaluable moderate important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 0.35 [0.04, 3.24]< 1 0% 2 studies (2/-) 82.2 % low not evaluable high important - viral clearance 0.90 [0.77, 1.05]> 1 0% 2 studies (2/-) 9.5 % low not evaluable high important - viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 1 0% 1 study (1/-) 13.7 % NA not evaluable important - viral clearance by day 7 0.91 [0.77, 1.08]> 1 0% 2 studies (2/-) 13.7 % low not evaluable high important - ICU admission 0.64 [0.25, 1.62]< 1 5% 2 studies (2/-) 82.6 % some concern not evaluable moderate non important - recovery 0.54 [0.15, 1.94]> 1 0% 1 study (1/-) 17.3 % NA not evaluable non important - 00 serious adverse events 0.77 [0.48, 1.22]< 1 0% 3 studies (3/-) 86.7 % some concern not evaluable moderate important - adverse events 3.09 [0.43, 22.21]< 1 91% 3 studies (3/-) 13.2 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
